IN THE CLAIMS:

Claims 1, 2, and 16 are amended herein. Claims 21-23 are new. All of the pending claims 1-7, 10-12, 16-18, and 20-23 are presented below. Withdrawn claims 13-15 are to be canceled. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (Currently amended) A method for treating an NFkappaB regulated inflammatory condition comprising administering to a subject in need of such treatment a molecule consisting of an oligopeptide selected from Table 6 ~~or functional analogue thereof~~, said molecule capable of reducing production of NO by a cell.

2. (Currently amended) A method for treating an NFkappaB regulated inflammatory condition comprising administering to a subject in need of such treatment a molecule consisting of an oligopeptide selected from Table 6 ~~or functional analogue thereof~~ wherein said molecule is capable of modulating translocation and/or activity of a gene transcription factor present in a cell.

3. (Original) The method according to claim 1 wherein said molecule additionally is capable of modulating translocation and/or activity of a gene transcription factor present in said cell.

4. (Previously presented) The method according to claim 2 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.

5. (Original) The method according to claim 3 wherein said modulating translocation and/or activity of a gene transcription factor allows modulation of TNF-alpha production by said cell.

6. (Original) The method according to claim 5 wherein said TNF-alpha production is

reduced.

7. (Previously presented) The method according to claim 1 wherein said inflammatory condition comprises an acute inflammatory condition.

8. (Canceled).

9 (Canceled).

10. (Previously presented) The method according to claim 1 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising the molecule capable of reducing production of NO by a cell.

11. (Original) The method according to claim 10 wherein said pharmaceutical composition comprises at least two oligopeptides or functional analogues thereof capable of reducing production of NO by a cell.

12. (Original) The method according to claim 11 wherein said at least two oligopeptides are selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2) and VLPALP (SEQ ID NO:3).

13.-15. (Canceled).

16. (Currently amended) A method of treating an NFkappaB regulated inflammatory condition in a subject by reducing NO production by the subject's macrophages, the method comprising administering to the subject an oligopeptide selected from Table 6 ~~or functional analogue thereof~~ capable of reducing production of NO by a cell.

17. (Previously presented) The method according to claim 3 wherein said gene transcription factor comprises a NF-kappaB/Rel protein.

18. (Previously presented) The method according to claim 2 wherein said inflammatory condition comprises an acute inflammatory condition.

19. (Canceled).

20. (Previously presented) The method according to claim 2 wherein said treatment comprises administering to said subject a pharmaceutical composition comprising the molecule capable of reducing production of NO by a cell.

21. (New) The method according to claim 1, wherein the oligopeptide is selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), MTRV (SEQ ID NO: 42) and QVVC (SEQ ID NO: 43).

22. (New) The method according to claim 2, wherein the oligopeptide is selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), MTRV (SEQ ID NO: 42) and QVVC (SEQ ID NO: 43).

23. (New) The method according to claim 16, wherein the oligopeptide is selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), MTRV (SEQ ID NO: 42) and QVVC (SEQ ID NO: 43).